Clarity Pharmaceuticals’ COBRA Study Selected as Top-Rated Oral Presentation at EANM 2024

Clarity Pharmaceuticals announced in a press release that two abstracts showcasing its SAR-bisPSMA data have been selected for presentation at the European Association of Nuclear Medicine (EANM) 2024 Congress. One of these, the COBRA study, has been recognized as a Top-Rated Oral Presentation within the Oncology & Theranostics Scientific Program, emphasizing the significance of Clarity’s innovative work in the field of prostate cancer diagnostics and treatment. The EANM Congress, taking place October 19-23, 2024, is one of the premier global events in nuclear medicine.

The COBRA study focuses on the safety and efficacy of ⁶⁴Cu-SAR-bisPSMA, an advanced prostate-specific membrane antigen (PSMA) targeting agent designed for the imaging of prostate cancer lesions in patients with biochemical recurrence (BCR) of prostate cancer. This radiopharmaceutical is particularly significant for patients whose standard-of-care scans have been negative or inconclusive. The study demonstrated that ⁶⁴Cu-SAR-bisPSMA can effectively detect prostate cancer lesions in these BCR patients.

The second abstract, also accepted for an oral presentation, is a case report that showcases the potential of ⁶⁷Cu-SAR-bisPSMA, a theranostic agent, for treating metastatic castration-resistant prostate cancer (mCRPC). The case involved a heavily pretreated patient who achieved a complete response—including anatomical, molecular, and biochemical remission—after two cycles of ⁶⁷Cu-SAR-bisPSMA treatment.

Dr. Alan Taylor, Clarity’s executive chairperson, expressed enthusiasm about these developments, stating, “We are very excited about the trajectory of development for our optimized prostate-specific membrane antigen targeting agent, SAR-bisPSMA, for both imaging and therapy. The EANM Congress is one of the most prestigious conferences in nuclear medicine, and it is fantastic to receive this recognition from our industry.” Dr. Taylor emphasized that the SAR-bisPSMA platform was developed with a deep understanding of the limitations of first-generation PSMA-targeting molecules. By using novel chemistry, Clarity has optimized the molecule to increase uptake and retention in prostate cancer tumors, setting it apart from other available agents.

Dr. Taylor also highlighted the broader implications of the COBRA study and the case report, noting that these advancements are part of Clarity’s ongoing commitment to providing innovative treatment options for both adults and children with cancer. He added, “We are excited to share this remarkable data as we continue to adhere to the highest standards of clinical research, work with world-class clinical sites and generate promising results, while continuously expanding the platform into new indications, targeting high unmet need in the oncology field, so that we can positively impact outcomes for patients in need of innovative treatment options.”

The COBRA study and case report will both be presented on October 21, 2024.